Drugs interactions for Opzelura®

  • 371 Major drug interactions (including ingredients like Abametapir, Abatacept, Acalabrutinib)
  • 248 Moderate drug interactions (including ingredients like Acebutolol, Acoramidis, Albendazole)
  • 446 Minor drug interactions (including ingredients like Abacavir, Abrocitinib, Aceclofenac)
1065 interactions for Opzelura®
A therapy excluded from this list of known interactions does not necessarily mean that no interactions exist between that therapy and and Opzelura®.
Abametapir
The serum concentration of Ruxolitinib can be increased when it is combined with Abametapir.
Abatacept
The metabolism of Ruxolitinib can be increased when combined with Abatacept.
Acalabrutinib
The metabolism of Ruxolitinib can be decreased when combined with Acalabrutinib.
Acetaminophen
The metabolism of Ruxolitinib can be increased when combined with Acetaminophen.
Acetazolamide
The serum concentration of Ruxolitinib can be increased when it is combined with Acetazolamide.
Acetyl sulfisoxazole
The metabolism of Ruxolitinib can be decreased when combined with Acetyl sulfisoxazole.
Adagrasib
The serum concentration of Ruxolitinib can be increased when it is combined with Adagrasib.
Adalimumab
The metabolism of Ruxolitinib can be increased when combined with Adalimumab.
Adenovirus type 7 vaccine live
The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Ruxolitinib.
Aldesleukin
The serum concentration of Ruxolitinib can be increased when it is combined with Aldesleukin.
Alemtuzumab
The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Ruxolitinib.
Amobarbital
The metabolism of Ruxolitinib can be increased when combined with Amobarbital.
Anakinra
The metabolism of Ruxolitinib can be increased when combined with Anakinra.
Anifrolumab
The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Anifrolumab.
Antilymphocyte immunoglobulin (horse)
The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Antilymphocyte immunoglobulin (horse).
Antithymocyte immunoglobulin (rabbit)
The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Ruxolitinib.
Apremilast
The metabolism of Ruxolitinib can be increased when combined with Apremilast.
Aprepitant
The metabolism of Ruxolitinib can be decreased when combined with Aprepitant.
Arsenic trioxide
The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Ruxolitinib.
Asunaprevir
The metabolism of Ruxolitinib can be increased when combined with Asunaprevir.
Atovaquone
The metabolism of Ruxolitinib can be decreased when combined with Atovaquone.
Avacincaptad pegol
The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Avacincaptad pegol.
Avacopan
The serum concentration of Ruxolitinib can be increased when it is combined with Avacopan.
Avapritinib
The metabolism of Ruxolitinib can be decreased when combined with Avapritinib.
Azacitidine
The risk or severity of adverse effects can be increased when Azacitidine is combined with Ruxolitinib.
Azathioprine
The risk or severity of adverse effects can be increased when Azathioprine is combined with Ruxolitinib.
Bacillus calmette-guerin substrain tice live antigen
The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Ruxolitinib.
Baricitinib
The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Baricitinib.
Basiliximab
The risk or severity of adverse effects can be increased when Basiliximab is combined with Ruxolitinib.
Beclomethasone dipropionate
The metabolism of Ruxolitinib can be increased when combined with Beclomethasone dipropionate.
Belatacept
The risk or severity of adverse effects can be increased when Belatacept is combined with Ruxolitinib.
Belimumab
The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Belimumab.
Belinostat
The risk or severity of adverse effects can be increased when Belinostat is combined with Ruxolitinib.
Belumosudil
The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Belumosudil.
Bendamustine
The risk or severity of adverse effects can be increased when Bendamustine is combined with Ruxolitinib.
Betamethasone
The metabolism of Ruxolitinib can be increased when combined with Betamethasone.
Bexarotene
The metabolism of Ruxolitinib can be increased when combined with Bexarotene.
Bicalutamide
The metabolism of Ruxolitinib can be decreased when combined with Bicalutamide.
Bimekizumab
The metabolism of Ruxolitinib can be increased when combined with Bimekizumab.
Bleomycin
The risk or severity of adverse effects can be increased when Bleomycin is combined with Ruxolitinib.
Blinatumomab
The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Blinatumomab.
Bortezomib
The risk or severity of adverse effects can be increased when Bortezomib is combined with Ruxolitinib.
Bosentan
The metabolism of Ruxolitinib can be increased when combined with Bosentan.
Bosutinib
The metabolism of Ruxolitinib can be decreased when combined with Bosutinib.
Brentuximab vedotin
The serum concentration of Ruxolitinib can be increased when it is combined with Brentuximab vedotin.
Brodalumab
The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Brodalumab.
Budesonide
The metabolism of Ruxolitinib can be increased when combined with Budesonide.
Buprenorphine
The metabolism of Ruxolitinib can be decreased when combined with Buprenorphine.
Busulfan
The risk or severity of adverse effects can be increased when Busulfan is combined with Ruxolitinib.
Butalbital
The metabolism of Ruxolitinib can be increased when combined with Butalbital.
Cabazitaxel
The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Ruxolitinib.
Calcitriol
The metabolism of Ruxolitinib can be increased when combined with Calcitriol.
Canakinumab
The metabolism of Ruxolitinib can be increased when combined with Canakinumab.
Cannabidiol
The serum concentration of Ruxolitinib can be increased when it is combined with Cannabidiol.
Carboplatin
The risk or severity of adverse effects can be increased when Carboplatin is combined with Ruxolitinib.
Carfilzomib
The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Carfilzomib.
Carmustine
The risk or severity of adverse effects can be increased when Carmustine is combined with Ruxolitinib.
Certolizumab pegol
The metabolism of Ruxolitinib can be increased when combined with Certolizumab pegol.
Chikungunya vaccine (live, attenuated)
The risk or severity of infection can be increased when Chikungunya vaccine (live, attenuated) is combined with Ruxolitinib.
Chlorambucil
The risk or severity of adverse effects can be increased when Chlorambucil is combined with Ruxolitinib.
Chloramphenicol
The serum concentration of Ruxolitinib can be increased when it is combined with Chloramphenicol.
Chlorpromazine
The metabolism of Ruxolitinib can be increased when combined with Chlorpromazine.
Ciclesonide
The risk or severity of adverse effects can be increased when Ciclesonide is combined with Ruxolitinib.
Cimetidine
The metabolism of Ruxolitinib can be decreased when combined with Cimetidine.
Ciprofloxacin
The metabolism of Ruxolitinib can be decreased when combined with Ciprofloxacin.
Cisplatin
The risk or severity of adverse effects can be increased when Cisplatin is combined with Ruxolitinib.
Citalopram
The metabolism of Ruxolitinib can be decreased when combined with Citalopram.
Clobazam
The metabolism of Ruxolitinib can be increased when combined with Clobazam.
Clobetasol propionate
The metabolism of Ruxolitinib can be increased when combined with Clobetasol propionate.
Clofarabine
The risk or severity of adverse effects can be increased when Clofarabine is combined with Ruxolitinib.
Clopidogrel
The metabolism of Ruxolitinib can be decreased when combined with Clopidogrel.
Cobicistat
The serum concentration of Ruxolitinib can be increased when it is combined with Cobicistat.
Corticotropin
The metabolism of Ruxolitinib can be increased when combined with Corticotropin.
Cortisone acetate
The metabolism of Ruxolitinib can be increased when combined with Cortisone acetate.
Crovalimab
The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Crovalimab.
Cyclophosphamide
The metabolism of Ruxolitinib can be increased when combined with Cyclophosphamide.
Cyclosporine
Ruxolitinib may increase the immunosuppressive activities of Cyclosporine.
Cytarabine
The risk or severity of adverse effects can be increased when Cytarabine is combined with Ruxolitinib.
Dacarbazine
The risk or severity of adverse effects can be increased when Dacarbazine is combined with Ruxolitinib.
Dactinomycin
The risk or severity of adverse effects can be increased when Dactinomycin is combined with Ruxolitinib.
Dalfopristin
The metabolism of Ruxolitinib can be decreased when combined with Dalfopristin.
Danicopan
The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Danicopan.
Dapsone
The metabolism of Ruxolitinib can be increased when combined with Dapsone.
Darunavir
The serum concentration of Ruxolitinib can be increased when it is combined with Darunavir.
Dasatinib
The metabolism of Ruxolitinib can be decreased when combined with Dasatinib.
Daunorubicin
The serum concentration of Ruxolitinib can be increased when it is combined with Daunorubicin.
Decitabine
The risk or severity of adverse effects can be increased when Decitabine is combined with Ruxolitinib.
Deferasirox
The metabolism of Ruxolitinib can be increased when combined with Deferasirox.
Deflazacort
The metabolism of Ruxolitinib can be increased when combined with Deflazacort.
Delafloxacin
The metabolism of Ruxolitinib can be increased when combined with Delafloxacin.
Desipramine
The serum concentration of Ruxolitinib can be increased when it is combined with Desipramine.
Desoximetasone
The risk or severity of adverse effects can be increased when Desoximetasone is combined with Ruxolitinib.
Desvenlafaxine
The metabolism of Ruxolitinib can be decreased when combined with Desvenlafaxine.
Deucravacitinib
The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Deucravacitinib.
Dexamethasone acetate
The metabolism of Ruxolitinib can be increased when combined with Dexamethasone acetate.
Dexrazoxane
The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Ruxolitinib.
Dextropropoxyphene
The serum concentration of Ruxolitinib can be increased when it is combined with Dextropropoxyphene.
Dicloxacillin
The metabolism of Ruxolitinib can be increased when combined with Dicloxacillin.
Dihydroergotamine
The serum concentration of Ruxolitinib can be increased when it is combined with Dihydroergotamine.
Dimethyl fumarate
The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Dimethyl fumarate.
Dimethyl sulfoxide
The serum concentration of Ruxolitinib can be increased when it is combined with Dimethyl sulfoxide.
Dinutuximab
The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Dinutuximab.
Diosmin
The serum concentration of Ruxolitinib can be increased when it is combined with Diosmin.
Diroximel fumarate
The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Diroximel fumarate.
Docetaxel
The serum concentration of Ruxolitinib can be increased when it is combined with Docetaxel.
Doconexent
The metabolism of Ruxolitinib can be decreased when combined with Doconexent.
Doxorubicin
The serum concentration of Ruxolitinib can be increased when it is combined with Doxorubicin.
Dronabinol
The metabolism of Ruxolitinib can be decreased when combined with Dronabinol.
Echinacea
The metabolism of Ruxolitinib can be increased when combined with Echinacea.
Eculizumab
The risk or severity of adverse effects can be increased when Eculizumab is combined with Ruxolitinib.
Efgartigimod alfa
The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Efgartigimod alfa.
Elafibranor
The metabolism of Ruxolitinib can be increased when combined with Elafibranor.
Emapalumab
The metabolism of Ruxolitinib can be increased when combined with Emapalumab.
Enasidenib
The metabolism of Ruxolitinib can be increased when combined with Enasidenib.
Encorafenib
The metabolism of Ruxolitinib can be increased when combined with Encorafenib.
Epinephrine
The serum concentration of Ruxolitinib can be increased when it is combined with Epinephrine.
Epirubicin
The risk or severity of adverse effects can be increased when Epirubicin is combined with Ruxolitinib.
Eribulin
The risk or severity of adverse effects can be increased when Eribulin is combined with Ruxolitinib.
Erlotinib
The serum concentration of Ruxolitinib can be increased when it is combined with Erlotinib.
Esketamine
The metabolism of Ruxolitinib can be increased when combined with Esketamine.
Eslicarbazepine acetate
The metabolism of Ruxolitinib can be increased when combined with Eslicarbazepine acetate.
Estradiol acetate
The metabolism of Ruxolitinib can be increased when combined with Estradiol acetate.
Estradiol cypionate
The metabolism of Ruxolitinib can be increased when combined with Estradiol cypionate.
Estradiol valerate
The metabolism of Ruxolitinib can be increased when combined with Estradiol valerate.
Estrone sulfate
The metabolism of Ruxolitinib can be decreased when combined with Estrone sulfate.
Etanercept
The metabolism of Ruxolitinib can be increased when combined with Etanercept.
Ethambutol
The metabolism of Ruxolitinib can be decreased when combined with Ethambutol.
Ethanol
The metabolism of Ruxolitinib can be increased when combined with Ethanol.
Etoposide
The risk or severity of adverse effects can be increased when Etoposide is combined with Ruxolitinib.
Etravirine
The metabolism of Ruxolitinib can be increased when combined with Etravirine.
Everolimus
The risk or severity of adverse effects can be increased when Everolimus is combined with Ruxolitinib.
Felbamate
The metabolism of Ruxolitinib can be increased when combined with Felbamate.
Fenofibrate
The metabolism of Ruxolitinib can be decreased when combined with Fenofibrate.
Fexinidazole
The serum concentration of Ruxolitinib can be increased when it is combined with Fexinidazole.
Flecainide
The metabolism of Ruxolitinib can be decreased when combined with Flecainide.
Floxuridine
The metabolism of Ruxolitinib can be decreased when combined with Floxuridine.
Flucytosine
The risk or severity of adverse effects can be increased when Flucytosine is combined with Ruxolitinib.
Fludarabine
The risk or severity of adverse effects can be increased when Fludarabine is combined with Ruxolitinib.
Fludrocortisone
The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Ruxolitinib.
Flunisolide
The metabolism of Ruxolitinib can be increased when combined with Flunisolide.
Fluocinolone acetonide
The metabolism of Ruxolitinib can be increased when combined with Fluocinolone acetonide.
Fluocinonide
The metabolism of Ruxolitinib can be increased when combined with Fluocinonide.
Fluorometholone
The risk or severity of adverse effects can be increased when Fluorometholone is combined with Ruxolitinib.
Fluorouracil
The metabolism of Ruxolitinib can be decreased when combined with Fluorouracil.
Fluoxetine
The metabolism of Ruxolitinib can be decreased when combined with Fluoxetine.
Fluticasone furoate
The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Fluticasone furoate.
Fluticasone propionate
The serum concentration of Ruxolitinib can be increased when it is combined with Fluticasone propionate.
Fluvastatin
The metabolism of Ruxolitinib can be decreased when combined with Fluvastatin.
Fluvoxamine
The metabolism of Ruxolitinib can be decreased when combined with Fluvoxamine.
Fosamprenavir
The serum concentration of Ruxolitinib can be increased when it is combined with Fosamprenavir.
Fosaprepitant
The metabolism of Ruxolitinib can be increased when combined with Fosaprepitant.
Fosnetupitant
The metabolism of Ruxolitinib can be decreased when combined with Fosnetupitant.
Fostamatinib
The serum concentration of Ruxolitinib can be increased when it is combined with Fostamatinib.
Fusidic acid
The metabolism of Ruxolitinib can be decreased when combined with Fusidic acid.
Gemcitabine
The risk or severity of adverse effects can be increased when Gemcitabine is combined with Ruxolitinib.
Gemfibrozil
The metabolism of Ruxolitinib can be decreased when combined with Gemfibrozil.
Gemtuzumab ozogamicin
The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ruxolitinib.
Genistein
The metabolism of Ruxolitinib can be increased when combined with Genistein.
Ginkgo biloba
The metabolism of Ruxolitinib can be decreased when combined with Ginkgo biloba.
Glatiramer
The risk or severity of adverse effects can be increased when Glatiramer is combined with Ruxolitinib.
Glecaprevir
The metabolism of Ruxolitinib can be decreased when combined with Glecaprevir.
Glyburide
The metabolism of Ruxolitinib can be decreased when combined with Glyburide.
Glycerol phenylbutyrate
The metabolism of Ruxolitinib can be increased when combined with Glycerol phenylbutyrate.
Golimumab
The metabolism of Ruxolitinib can be increased when combined with Golimumab.
Grapefruit
The serum concentration of Ruxolitinib can be increased when it is combined with Grapefruit.
Griseofulvin
The metabolism of Ruxolitinib can be increased when combined with Griseofulvin.
Guselkumab
The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Guselkumab.
Human adenovirus e serotype 4 strain cl-68578 antigen
The risk or severity of infection can be increased when Human adenovirus e serotype 4 strain cl-68578 antigen is combined with Ruxolitinib.
Hydralazine
The serum concentration of Ruxolitinib can be increased when it is combined with Hydralazine.
Hydrocortisone
The metabolism of Ruxolitinib can be increased when combined with Hydrocortisone.
Hydrocortisone acetate
The metabolism of Ruxolitinib can be increased when combined with Hydrocortisone acetate.
Hydrocortisone butyrate
The metabolism of Ruxolitinib can be increased when combined with Hydrocortisone butyrate.
Hydrocortisone succinate
The metabolism of Ruxolitinib can be increased when combined with Hydrocortisone succinate.
Hydroxychloroquine
The risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Ruxolitinib.
Hydroxyurea
The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Ruxolitinib.
Ibritumomab tiuxetan
The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ruxolitinib.
Ibrutinib
The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Ibrutinib.
Idarubicin
The risk or severity of adverse effects can be increased when Idarubicin is combined with Ruxolitinib.
Idelalisib
The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Idelalisib.
Ifosfamide
The metabolism of Ruxolitinib can be increased when combined with Ifosfamide.
Indomethacin
The risk or severity of adverse effects can be increased when Indomethacin is combined with Ruxolitinib.
Infliximab
The metabolism of Ruxolitinib can be increased when combined with Infliximab.
Interferon alfa-2b
The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Ruxolitinib.
Interferon alfa-n3
The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Ruxolitinib.
Interferon beta-1b
The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Ruxolitinib.
Interferon gamma-1b
The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Ruxolitinib.
Iptacopan
The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Iptacopan.
Irbesartan
The serum concentration of Ruxolitinib can be increased when it is combined with Irbesartan.
Irinotecan
The risk or severity of adverse effects can be increased when Irinotecan is combined with Ruxolitinib.
Isavuconazonium
The metabolism of Ruxolitinib can be increased when combined with Isavuconazonium.
Isoniazid
The metabolism of Ruxolitinib can be decreased when combined with Isoniazid.
Ixabepilone
The risk or severity of adverse effects can be increased when Ixabepilone is combined with Ruxolitinib.
Ixekizumab
The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Ixekizumab.
Lapatinib
The metabolism of Ruxolitinib can be decreased when combined with Lapatinib.
Lenalidomide
The risk or severity of adverse effects can be increased when Lenalidomide is combined with Ruxolitinib.
Letermovir
The serum concentration of Ruxolitinib can be increased when it is combined with Letermovir.
Linagliptin
The metabolism of Ruxolitinib can be decreased when combined with Linagliptin.
Linezolid
The risk or severity of adverse effects can be increased when Linezolid is combined with Ruxolitinib.
Lomitapide
The metabolism of Ruxolitinib can be decreased when combined with Lomitapide.
Lomustine
The risk or severity of adverse effects can be increased when Lomustine is combined with Ruxolitinib.
Lorlatinib
The metabolism of Ruxolitinib can be increased when combined with Lorlatinib.
Mechlorethamine
The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Ruxolitinib.
Medroxyprogesterone acetate
The metabolism of Ruxolitinib can be increased when combined with Medroxyprogesterone acetate.
Melphalan
The risk or severity of adverse effects can be increased when Melphalan is combined with Ruxolitinib.
Mepolizumab
The risk or severity of adverse effects can be increased when Mepolizumab is combined with Ruxolitinib.
Mercaptopurine
The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Ruxolitinib.
Methadone
The serum concentration of Ruxolitinib can be increased when it is combined with Methadone.
Methotrexate
The risk or severity of adverse effects can be increased when Methotrexate is combined with Ruxolitinib.
Methylene blue
The serum concentration of Ruxolitinib can be increased when it is combined with Methylene blue.
Methylergometrine
The serum concentration of Ruxolitinib can be increased when it is combined with Methylergometrine.
Methylprednisolone
The metabolism of Ruxolitinib can be increased when combined with Methylprednisolone.
Metronidazole
The serum concentration of Ruxolitinib can be increased when it is combined with Metronidazole.
Metyrapone
The metabolism of Ruxolitinib can be increased when combined with Metyrapone.
Miconazole
The metabolism of Ruxolitinib can be decreased when combined with Miconazole.
Midazolam
The serum concentration of Ruxolitinib can be increased when it is combined with Midazolam.
Mifepristone
The metabolism of Ruxolitinib can be increased when combined with Mifepristone.
Milnacipran
The metabolism of Ruxolitinib can be decreased when combined with Milnacipran.
Mirikizumab
The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Mirikizumab.
Mirtazapine
The metabolism of Ruxolitinib can be decreased when combined with Mirtazapine.
Mitomycin
The risk or severity of adverse effects can be increased when Mitomycin is combined with Ruxolitinib.
Mitoxantrone
The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Ruxolitinib.
Mometasone furoate
The metabolism of Ruxolitinib can be increased when combined with Mometasone furoate.
Monomethyl fumarate
The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Monomethyl fumarate.
Mycophenolate mofetil
The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Ruxolitinib.
Mycophenolic acid
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Ruxolitinib.
Nafcillin
The metabolism of Ruxolitinib can be increased when combined with Nafcillin.
Natalizumab
The risk or severity of immunosuppression can be increased when Ruxolitinib is combined with Natalizumab.
Nelarabine
The risk or severity of adverse effects can be increased when Nelarabine is combined with Ruxolitinib.
Netupitant
The metabolism of Ruxolitinib can be decreased when combined with Netupitant.
Niacin
The serum concentration of Ruxolitinib can be increased when it is combined with Niacin.
Nilutamide
The metabolism of Ruxolitinib can be decreased when combined with Nilutamide.
Nirogacestat
The metabolism of Ruxolitinib can be increased when combined with Nirogacestat.
Norgestimate
The metabolism of Ruxolitinib can be increased when combined with Norgestimate.
Obinutuzumab
The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Obinutuzumab.
Ocrelizumab
The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Ocrelizumab.
Ofatumumab
The risk or severity of adverse effects can be increased when Ofatumumab is combined with Ruxolitinib.
Olanzapine
The metabolism of Ruxolitinib can be decreased when combined with Olanzapine.
Olaparib
The metabolism of Ruxolitinib can be decreased when combined with Olaparib.
Olutasidenib
The metabolism of Ruxolitinib can be increased when combined with Olutasidenib.
Oritavancin
The metabolism of Ruxolitinib can be increased when combined with Oritavancin.
Orphenadrine
The metabolism of Ruxolitinib can be decreased when combined with Orphenadrine.
Osilodrostat
The metabolism of Ruxolitinib can be decreased when combined with Osilodrostat.
Oxaliplatin
The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Ruxolitinib.
Oxandrolone
The metabolism of Ruxolitinib can be decreased when combined with Oxandrolone.
Oxcarbazepine
The metabolism of Ruxolitinib can be increased when combined with Oxcarbazepine.
Oxybutynin
The serum concentration of Ruxolitinib can be increased when it is combined with Oxybutynin.
Ozanimod
The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Ozanimod.
Paclitaxel
The metabolism of Ruxolitinib can be increased when combined with Paclitaxel.
Palbociclib
The metabolism of Ruxolitinib can be decreased when combined with Palbociclib.
Palovarotene
The metabolism of Ruxolitinib can be increased when combined with Palovarotene.
Panobinostat
The risk or severity of adverse effects can be increased when Panobinostat is combined with Ruxolitinib.
Paroxetine
The metabolism of Ruxolitinib can be decreased when combined with Paroxetine.
Pazopanib
The metabolism of Ruxolitinib can be decreased when combined with Pazopanib.
Pegaspargase
The risk or severity of adverse effects can be increased when Pegaspargase is combined with Ruxolitinib.
Pegcetacoplan
The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Pegcetacoplan.
Peginterferon alfa-2a
The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Ruxolitinib.
Peginterferon alfa-2b
The metabolism of Ruxolitinib can be increased when combined with Peginterferon alfa-2b.
Peginterferon beta-1a
The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Peginterferon beta-1a.
Pemetrexed
The risk or severity of adverse effects can be increased when Pemetrexed is combined with Ruxolitinib.
Penicillamine
The risk or severity of adverse effects can be increased when Penicillamine is combined with Ruxolitinib.
Pentostatin
The risk or severity of adverse effects can be increased when Pentostatin is combined with Ruxolitinib.
Perampanel
The metabolism of Ruxolitinib can be increased when combined with Perampanel.
Phenylalanine
The risk or severity of adverse effects can be increased when Phenylalanine is combined with Ruxolitinib.
Pimecrolimus
The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Ruxolitinib.
Piperine
The serum concentration of Ruxolitinib can be increased when it is combined with Piperine.
Pirfenidone
The risk or severity of adverse effects can be increased when Pirfenidone is combined with Ruxolitinib.
Pirtobrutinib
The metabolism of Ruxolitinib can be decreased when combined with Pirtobrutinib.
Pomalidomide
The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Pomalidomide.
Ponatinib
The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Ponatinib.
Ponesimod
The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Ponesimod.
Pozelimab
The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Pozelimab.
Pralatrexate
The risk or severity of adverse effects can be increased when Pralatrexate is combined with Ruxolitinib.
Pralsetinib
The metabolism of Ruxolitinib can be increased when combined with Pralsetinib.
Prednisolone
The metabolism of Ruxolitinib can be increased when combined with Prednisolone.
Prednisolone acetate
The metabolism of Ruxolitinib can be increased when combined with Prednisolone acetate.
Prednisolone phosphate
The metabolism of Ruxolitinib can be increased when combined with Prednisolone phosphate.
Prednisone
The risk or severity of adverse effects can be increased when Prednisone is combined with Ruxolitinib.
Primaquine
The metabolism of Ruxolitinib can be decreased when combined with Primaquine.
Probenecid
The metabolism of Ruxolitinib can be increased when combined with Probenecid.
Procarbazine
The risk or severity of adverse effects can be increased when Procarbazine is combined with Ruxolitinib.
Progesterone
The metabolism of Ruxolitinib can be decreased when combined with Progesterone.
Promethazine
The metabolism of Ruxolitinib can be decreased when combined with Promethazine.
Propofol
The metabolism of Ruxolitinib can be decreased when combined with Propofol.
Quinidine
The metabolism of Ruxolitinib can be decreased when combined with Quinidine.
Quinine
The metabolism of Ruxolitinib can be increased when combined with Quinine.
Quinupristin
The metabolism of Ruxolitinib can be decreased when combined with Quinupristin.
Raloxifene
The serum concentration of Ruxolitinib can be increased when it is combined with Raloxifene.
Ranolazine
The metabolism of Ruxolitinib can be decreased when combined with Ranolazine.
Ravulizumab
The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Ravulizumab.
Remdesivir
The metabolism of Ruxolitinib can be decreased when combined with Remdesivir.
Rifabutin
The metabolism of Ruxolitinib can be increased when combined with Rifabutin.
Rilonacept
The metabolism of Ruxolitinib can be increased when combined with Rilonacept.
Rilpivirine
The metabolism of Ruxolitinib can be decreased when combined with Rilpivirine.
Risankizumab
The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Risankizumab.
Rituximab
The risk or severity of adverse effects can be increased when Rituximab is combined with Ruxolitinib.
Ropeginterferon alfa-2b
The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Ropeginterferon alfa-2b.
Rozanolixizumab
The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Rozanolixizumab.
Rubella virus vaccine
The risk or severity of infection can be increased when Rubella virus vaccine is combined with Ruxolitinib.
Rufinamide
The metabolism of Ruxolitinib can be increased when combined with Rufinamide.
Sarilumab
The metabolism of Ruxolitinib can be increased when combined with Sarilumab.
Secobarbital
The metabolism of Ruxolitinib can be increased when combined with Secobarbital.
Secukinumab
The metabolism of Ruxolitinib can be increased when combined with Secukinumab.
Sertraline
The metabolism of Ruxolitinib can be decreased when combined with Sertraline.
Sildenafil
The metabolism of Ruxolitinib can be decreased when combined with Sildenafil.
Siltuximab
The metabolism of Ruxolitinib can be increased when combined with Siltuximab.
Simvastatin
The metabolism of Ruxolitinib can be decreased when combined with Simvastatin.
Siponimod
The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Siponimod.
Sirolimus
The risk or severity of adverse effects can be increased when Sirolimus is combined with Ruxolitinib.
Smallpox (Vaccinia) Vaccine, Live
The risk or severity of infection can be increased when Smallpox (Vaccinia) Vaccine, Live is combined with Ruxolitinib.
Sorafenib
The risk or severity of adverse effects can be increased when Sorafenib is combined with Ruxolitinib.
Sotorasib
The serum concentration of Ruxolitinib can be decreased when it is combined with Sotorasib.
Spesolimab
The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Spesolimab.
Stiripentol
The metabolism of Ruxolitinib can be decreased when combined with Stiripentol.
Streptozocin
The risk or severity of adverse effects can be increased when Streptozocin is combined with Ruxolitinib.
Sulfadiazine
The metabolism of Ruxolitinib can be decreased when combined with Sulfadiazine.
Sulfamethizole
The metabolism of Ruxolitinib can be decreased when combined with Sulfamethizole.
Sulfasalazine
The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Ruxolitinib.
Sunitinib
The risk or severity of adverse effects can be increased when Sunitinib is combined with Ruxolitinib.
Sutimlimab
The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Sutimlimab.
Tamoxifen
The metabolism of Ruxolitinib can be increased when combined with Tamoxifen.
Tecovirimat
The metabolism of Ruxolitinib can be increased when combined with Tecovirimat.
Temozolomide
The risk or severity of adverse effects can be increased when Temozolomide is combined with Ruxolitinib.
Temsirolimus
The risk or severity of adverse effects can be increased when Temsirolimus is combined with Ruxolitinib.
Teniposide
The serum concentration of Ruxolitinib can be increased when it is combined with Teniposide.
Tepotinib
The metabolism of Ruxolitinib can be decreased when combined with Tepotinib.
Teprotumumab
The risk or severity of adverse effects can be increased when Teprotumumab is combined with Ruxolitinib.
Terbinafine
The metabolism of Ruxolitinib can be increased when combined with Terbinafine.
Teriflunomide
The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Teriflunomide.
Testosterone
The metabolism of Ruxolitinib can be increased when combined with Testosterone.
Tetracycline
The serum concentration of Ruxolitinib can be increased when it is combined with Tetracycline.
Thalidomide
The metabolism of Ruxolitinib can be increased when combined with Thalidomide.
Thiotepa
The risk or severity of adverse effects can be increased when Thiotepa is combined with Ruxolitinib.
Ticagrelor
The metabolism of Ruxolitinib can be decreased when combined with Ticagrelor.
Ticlopidine
The metabolism of Ruxolitinib can be decreased when combined with Ticlopidine.
Tioguanine
The risk or severity of adverse effects can be increased when Tioguanine is combined with Ruxolitinib.
Tixocortol
The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Tixocortol.
Tocilizumab
The metabolism of Ruxolitinib can be increased when combined with Tocilizumab.
Topiramate
The metabolism of Ruxolitinib can be increased when combined with Topiramate.
Topotecan
The risk or severity of adverse effects can be increased when Topotecan is combined with Ruxolitinib.
Torasemide
The metabolism of Ruxolitinib can be decreased when combined with Torasemide.
Trabectedin
The risk or severity of adverse effects can be increased when Trabectedin is combined with Ruxolitinib.
Tranylcypromine
The metabolism of Ruxolitinib can be decreased when combined with Tranylcypromine.
Trastuzumab emtansine
The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Ruxolitinib.
Treosulfan
The serum concentration of Ruxolitinib can be increased when it is combined with Treosulfan.
Triamcinolone
The metabolism of Ruxolitinib can be increased when combined with Triamcinolone.
Triclabendazole
The serum concentration of Ruxolitinib can be increased when it is combined with Triclabendazole.
Trifluridine
The risk or severity of adverse effects can be increased when Trifluridine is combined with Ruxolitinib.
Typhoid Vaccine Live
The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Ruxolitinib.
Upadacitinib
The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Upadacitinib.
Valdecoxib
The metabolism of Ruxolitinib can be decreased when combined with Valdecoxib.
Valproic acid
The serum concentration of Ruxolitinib can be increased when it is combined with Valproic acid.
Valsartan
The metabolism of Ruxolitinib can be decreased when combined with Valsartan.
Varicella zoster vaccine (live/attenuated)
The risk or severity of infection can be increased when Varicella zoster vaccine (live/attenuated) is combined with Ruxolitinib.
Vedolizumab
The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Vedolizumab.
Vemurafenib
The metabolism of Ruxolitinib can be increased when combined with Vemurafenib.
Venetoclax
The metabolism of Ruxolitinib can be decreased when combined with Venetoclax.
Vilanterol
The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Vilanterol.
Vinblastine
The metabolism of Ruxolitinib can be increased when combined with Vinblastine.
Vincristine
The risk or severity of adverse effects can be increased when Vincristine is combined with Ruxolitinib.
Vinorelbine
The risk or severity of adverse effects can be increased when Vinorelbine is combined with Ruxolitinib.
Vitamin E
The metabolism of Ruxolitinib can be increased when combined with Vitamin E.
Voclosporin
The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Voclosporin.
Vorasidenib
The metabolism of Ruxolitinib can be increased when combined with Vorasidenib.
Vorinostat
The risk or severity of adverse effects can be increased when Vorinostat is combined with Ruxolitinib.
Voxelotor
The serum concentration of Ruxolitinib can be increased when it is combined with Voxelotor.
Warfarin
The metabolism of Ruxolitinib can be increased when combined with Warfarin.
Yellow fever vaccine
The risk or severity of infection can be increased when Yellow fever vaccine is combined with Ruxolitinib.
Zafirlukast
The serum concentration of Ruxolitinib can be increased when it is combined with Zafirlukast.
Zidovudine
The risk or severity of adverse effects can be increased when Zidovudine is combined with Ruxolitinib.
Zilucoplan
The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Zilucoplan.
Ziprasidone
The metabolism of Ruxolitinib can be decreased when combined with Ziprasidone.
Acebutolol
Ruxolitinib may increase the bradycardic activities of Acebutolol.
Acoramidis
The serum concentration of Ruxolitinib can be increased when it is combined with Acoramidis.
Albendazole
The metabolism of Ruxolitinib can be decreased when combined with Albendazole.
Alfentanil
Ruxolitinib may increase the bradycardic activities of Alfentanil.
Allopurinol
The risk or severity of adverse effects can be increased when Allopurinol is combined with Ruxolitinib.
Alpelisib
The serum concentration of Ruxolitinib can be decreased when it is combined with Alpelisib.
Amikacin
Ruxolitinib may decrease the excretion rate of Amikacin which could result in a higher serum level.
Amiodarone
The metabolism of Ruxolitinib can be decreased when combined with Amiodarone.
Amlodipine
Ruxolitinib may increase the bradycardic activities of Amlodipine.
Anthrax immune globulin human
The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Ruxolitinib.
Apalutamide
The serum concentration of Ruxolitinib can be decreased when it is combined with Apalutamide.
Armodafinil
The metabolism of Ruxolitinib can be increased when combined with Armodafinil.
Articaine
The risk or severity of methemoglobinemia can be increased when Ruxolitinib is combined with Articaine.
Asciminib
The serum concentration of Ruxolitinib can be increased when it is combined with Asciminib.
AstraZeneca COVID-19 Vaccine
The therapeutic efficacy of AstraZeneca COVID-19 Vaccine can be decreased when used in combination with Ruxolitinib.
Atazanavir
The metabolism of Ruxolitinib can be decreased when combined with Atazanavir.
Atenolol
Ruxolitinib may increase the bradycardic activities of Atenolol.
Avanafil
The serum concentration of Avanafil can be increased when it is combined with Ruxolitinib.
Azithromycin
The metabolism of Ruxolitinib can be decreased when combined with Azithromycin.
Belzutifan
The serum concentration of Ruxolitinib can be decreased when it is combined with Belzutifan.
Bendroflumethiazide
Ruxolitinib may increase the bradycardic activities of Bendroflumethiazide.
Benzgalantamine
Ruxolitinib may increase the bradycardic activities of Benzgalantamine.
Benzocaine
The risk or severity of methemoglobinemia can be increased when Ruxolitinib is combined with Benzocaine.
Benzyl alcohol
The risk or severity of methemoglobinemia can be increased when Ruxolitinib is combined with Benzyl alcohol.
Beractant
Ruxolitinib may increase the bradycardic activities of Beractant.
Berotralstat
The serum concentration of Ruxolitinib can be increased when it is combined with Berotralstat.
Betaxolol
Ruxolitinib may increase the bradycardic activities of Betaxolol.
Bisoprolol
Ruxolitinib may increase the bradycardic activities of Bisoprolol.
Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated)
The therapeutic efficacy of Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) can be decreased when used in combination with Ruxolitinib.
Bretylium
Ruxolitinib may increase the bradycardic activities of Bretylium.
Bupivacaine
The risk or severity of methemoglobinemia can be increased when Ruxolitinib is combined with Bupivacaine.
Butamben
The risk or severity of methemoglobinemia can be increased when Ruxolitinib is combined with Butamben.
Calfactant
Ruxolitinib may increase the bradycardic activities of Calfactant.
Capecitabine
The serum concentration of Ruxolitinib can be increased when it is combined with Capecitabine.
Capreomycin
Ruxolitinib may decrease the excretion rate of Capreomycin which could result in a higher serum level.
Capsaicin
The risk or severity of methemoglobinemia can be increased when Ruxolitinib is combined with Capsaicin.
Carvedilol
Ruxolitinib may increase the bradycardic activities of Carvedilol.
Cenobamate
The serum concentration of Ruxolitinib can be decreased when it is combined with Cenobamate.
Cephalexin
The metabolism of Ruxolitinib can be decreased when combined with Cephalexin.
Ceritinib
Ruxolitinib may increase the bradycardic activities of Ceritinib.
Chloroprocaine
The risk or severity of methemoglobinemia can be increased when Ruxolitinib is combined with Chloroprocaine.
Cinchocaine
The risk or severity of methemoglobinemia can be increased when Ruxolitinib is combined with Cinchocaine.
Clarithromycin
The metabolism of Ruxolitinib can be decreased when combined with Clarithromycin.
Clevidipine
Ruxolitinib may increase the bradycardic activities of Clevidipine.
Clonidine
Ruxolitinib may increase the bradycardic activities of Clonidine.
Clostridium tetani toxoid antigen (formaldehyde inactivated)
The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Ruxolitinib.
Clozapine
The risk or severity of neutropenia can be increased when Ruxolitinib is combined with Clozapine.
Cobimetinib
The metabolism of Ruxolitinib can be decreased when combined with Cobimetinib.
Cocaine
The risk or severity of methemoglobinemia can be increased when Ruxolitinib is combined with Cocaine.
Colistin
Ruxolitinib may decrease the excretion rate of Colistin which could result in a higher serum level.
Conivaptan
The metabolism of Ruxolitinib can be decreased when combined with Conivaptan.
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Ruxolitinib.
Crizotinib
The metabolism of Ruxolitinib can be decreased when combined with Crizotinib.
Curcumin
The metabolism of Ruxolitinib can be decreased when combined with Curcumin.
Cyanocobalamin
The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Ruxolitinib.
Dabrafenib
The serum concentration of Ruxolitinib can be decreased when it is combined with Dabrafenib.
Dacomitinib
The metabolism of Ruxolitinib can be decreased when combined with Dacomitinib.
Danazol
The metabolism of Ruxolitinib can be decreased when combined with Danazol.
Darbepoetin alfa
The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Ruxolitinib.
Denosumab
The risk or severity of adverse effects can be increased when Denosumab is combined with Ruxolitinib.
Deutivacaftor
The serum concentration of Ruxolitinib can be increased when it is combined with Deutivacaftor.
Dexmedetomidine
Ruxolitinib may increase the bradycardic activities of Dexmedetomidine.
Digoxin
Ruxolitinib may increase the bradycardic activities of Digoxin.
Dihydroergocornine
The metabolism of Ruxolitinib can be decreased when combined with Dihydroergocornine.
Dihydroergocristine
The metabolism of Ruxolitinib can be decreased when combined with Dihydroergocristine.
Diltiazem
Ruxolitinib may increase the bradycardic activities of Diltiazem.
Diphenhydramine
The risk or severity of methemoglobinemia can be increased when Ruxolitinib is combined with Diphenhydramine.
Donepezil
Ruxolitinib may increase the bradycardic activities of Donepezil.
Doxazosin
The metabolism of Ruxolitinib can be decreased when combined with Doxazosin.
Dronedarone
The serum concentration of Ruxolitinib can be increased when it is combined with Dronedarone.
Drospirenone
The metabolism of Ruxolitinib can be decreased when combined with Drospirenone.
Duvelisib
The metabolism of Ruxolitinib can be decreased when combined with Duvelisib.
Dyclonine
The risk or severity of methemoglobinemia can be increased when Ruxolitinib is combined with Dyclonine.
Ebola Zaire vaccine (live, attenuated)
The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Ruxolitinib.
Efavirenz
The metabolism of Ruxolitinib can be decreased when combined with Efavirenz.
Elasomeran
The therapeutic efficacy of Moderna COVID-19 Vaccine can be decreased when used in combination with Ruxolitinib.
Elexacaftor
The metabolism of Ruxolitinib can be decreased when combined with Elexacaftor.
Elvitegravir
The metabolism of Ruxolitinib can be decreased when combined with Elvitegravir.
Enzalutamide
The serum concentration of Ruxolitinib can be decreased when it is combined with Enzalutamide.
Epcoritamab
The serum concentration of Ruxolitinib can be increased when it is combined with Epcoritamab.
Erdafitinib
The serum concentration of Ruxolitinib can be increased when it is combined with Erdafitinib.
Ergotamine
The metabolism of Ruxolitinib can be decreased when combined with Ergotamine.
Erythromycin
The serum concentration of Ruxolitinib can be increased when it is combined with Erythromycin.
Erythropoietin
The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Ruxolitinib.
Esmolol
Ruxolitinib may increase the bradycardic activities of Esmolol.
Estetrol
The metabolism of Ruxolitinib can be decreased when combined with Estetrol.
Ethosuximide
Ruxolitinib may increase the bradycardic activities of Ethosuximide.
Etrasimod
The risk or severity of immunosuppression can be increased when Ruxolitinib is combined with Etrasimod.
Fedratinib
The serum concentration of Ruxolitinib can be increased when it is combined with Fedratinib.
Felodipine
Ruxolitinib may increase the bradycardic activities of Felodipine.
Fentanyl
Ruxolitinib may increase the bradycardic activities of Fentanyl.
Fingolimod
Ruxolitinib may increase the immunosuppressive activities of Fingolimod.
Fluconazole
The serum concentration of Ruxolitinib can be increased when it is combined with Fluconazole.
Follitropin
The therapeutic efficacy of Follitropin can be decreased when used in combination with Ruxolitinib.
Galantamine
Ruxolitinib may increase the bradycardic activities of Galantamine.
Gentamicin
Ruxolitinib may decrease the excretion rate of Gentamicin which could result in a higher serum level.
Gilteritinib
The metabolism of Ruxolitinib can be decreased when combined with Gilteritinib.
Givinostat
The serum concentration of Ruxolitinib can be increased when it is combined with Givinostat.
Glofitamab
The serum concentration of Ruxolitinib can be increased when it is combined with Glofitamab.
Guanfacine
Ruxolitinib may increase the bradycardic activities of Guanfacine.
Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen
The therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Ruxolitinib.
Haloperidol
The serum concentration of Haloperidol can be increased when it is combined with Ruxolitinib.
Hepatitis A Vaccine
The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Ruxolitinib.
Hepatitis B Vaccine (Recombinant)
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Ruxolitinib.
Imatinib
The serum concentration of Ruxolitinib can be increased when it is combined with Imatinib.
Indinavir
The metabolism of Ruxolitinib can be decreased when combined with Indinavir.
Infigratinib
The metabolism of Ruxolitinib can be decreased when combined with Infigratinib.
Isradipine
Ruxolitinib may increase the bradycardic activities of Isradipine.
Itraconazole
The metabolism of Ruxolitinib can be decreased when combined with Itraconazole.
Ivabradine
Ruxolitinib may increase the bradycardic activities of Ivabradine.
Ivacaftor
The serum concentration of Ruxolitinib can be increased when it is combined with Ivacaftor.
Ivosidenib
The metabolism of Ruxolitinib can be increased when combined with Ivosidenib.
Janssen COVID-19 Vaccine
The therapeutic efficacy of Janssen COVID-19 Vaccine can be decreased when used in combination with Ruxolitinib.
Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated)
The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Ruxolitinib.
Ketoconazole
The metabolism of Ruxolitinib can be decreased when combined with Ketoconazole.
Labetalol
Ruxolitinib may increase the bradycardic activities of Labetalol.
Lacosamide
Ruxolitinib may increase the bradycardic activities of Lacosamide.
Lamotrigine
Ruxolitinib may increase the bradycardic activities of Lamotrigine.
Landiolol
Ruxolitinib may increase the bradycardic activities of Landiolol.
Lanreotide
Ruxolitinib may increase the bradycardic activities of Lanreotide.
Lefamulin
The serum concentration of Ruxolitinib can be increased when it is combined with Lefamulin.
Leflunomide
The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Leflunomide.
Levoketoconazole
The metabolism of Ruxolitinib can be decreased when combined with Levoketoconazole.
Levomenthol
Ruxolitinib may increase the bradycardic activities of Levomenthol.
Levothyroxine
The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Ruxolitinib.
Lidocaine
The risk or severity of methemoglobinemia can be increased when Ruxolitinib is combined with Lidocaine.
Liothyronine
The therapeutic efficacy of Liothyronine can be decreased when used in combination with Ruxolitinib.
Lithium carbonate
Ruxolitinib may decrease the excretion rate of Lithium carbonate which could result in a higher serum level.
Lonafarnib
The metabolism of Ruxolitinib can be decreased when combined with Lonafarnib.
Loperamide
Ruxolitinib may increase the bradycardic activities of Loperamide.
Lopinavir
The metabolism of Ruxolitinib can be decreased when combined with Lopinavir.
Lumacaftor
The serum concentration of Ruxolitinib can be decreased when it is combined with Lumacaftor.
Magnesium
The serum concentration of Magnesium can be decreased when it is combined with Ruxolitinib.
Magnesium sulfate
Ruxolitinib may increase the bradycardic activities of Magnesium sulfate.
Mavacamten
The serum concentration of Ruxolitinib can be decreased when it is combined with Mavacamten.
Measles virus vaccine live attenuated
The therapeutic efficacy of Measles virus vaccine live attenuated can be decreased when used in combination with Ruxolitinib.
Meloxicam
The risk or severity of methemoglobinemia can be increased when Ruxolitinib is combined with Meloxicam.
Meperidine
The metabolism of Ruxolitinib can be decreased when combined with Meperidine.
Mepivacaine
The risk or severity of methemoglobinemia can be increased when Ruxolitinib is combined with Mepivacaine.
Methimazole
The metabolism of Ruxolitinib can be decreased when combined with Methimazole.
Methoxy polyethylene glycol-epoetin beta
The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Ruxolitinib.
Methsuximide
Ruxolitinib may increase the bradycardic activities of Methsuximide.
Methyldopa
Ruxolitinib may increase the bradycardic activities of Methyldopa.
Metoprolol
Ruxolitinib may increase the bradycardic activities of Metoprolol.
Midodrine
Ruxolitinib may increase the bradycardic activities of Midodrine.
Midostaurin
The metabolism of Ruxolitinib can be decreased when combined with Midostaurin.
Modafinil
The metabolism of Ruxolitinib can be increased when combined with Modafinil.
Modified vaccinia ankara
The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Ruxolitinib.
mRNA-1345
The therapeutic efficacy of mRNA-1345 can be decreased when used in combination with Ruxolitinib.
Mumps virus strain B level jeryl lynn live antigen
The therapeutic efficacy of Mumps virus strain B level jeryl lynn live antigen can be decreased when used in combination with Ruxolitinib.
Nadolol
Ruxolitinib may increase the bradycardic activities of Nadolol.
Nebivolol
Ruxolitinib may increase the bradycardic activities of Nebivolol.
Nefazodone
The metabolism of Ruxolitinib can be decreased when combined with Nefazodone.
Nelfinavir
The metabolism of Ruxolitinib can be decreased when combined with Nelfinavir.
Neomycin
Ruxolitinib may decrease the excretion rate of Neomycin which could result in a higher serum level.
Nicardipine
Ruxolitinib may increase the bradycardic activities of Nicardipine.
Nifedipine
Ruxolitinib may increase the bradycardic activities of Nifedipine.
Nilotinib
The metabolism of Ruxolitinib can be decreased when combined with Nilotinib.
Nimodipine
Ruxolitinib may increase the bradycardic activities of Nimodipine.
Nintedanib
The metabolism of Ruxolitinib can be decreased when combined with Nintedanib.
Nisoldipine
Ruxolitinib may increase the bradycardic activities of Nisoldipine.
Norethisterone
The metabolism of Ruxolitinib can be decreased when combined with Norethisterone.
Nuvaxovid
The therapeutic efficacy of Nuvaxovid can be decreased when used in combination with Ruxolitinib.
Octreotide
The serum concentration of Ruxolitinib can be increased when it is combined with Octreotide.
Osimertinib
The metabolism of Ruxolitinib can be decreased when combined with Osimertinib.
Oxybuprocaine
The risk or severity of methemoglobinemia can be increased when Ruxolitinib is combined with Oxybuprocaine.
Pacritinib
The serum concentration of Ruxolitinib can be increased when it is combined with Pacritinib.
Palifermin
The therapeutic efficacy of Palifermin can be decreased when used in combination with Ruxolitinib.
Palopegteriparatide
The therapeutic efficacy of Palopegteriparatide can be decreased when used in combination with Ruxolitinib.
Parathyroid hormone
The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Ruxolitinib.
Pasireotide
Ruxolitinib may increase the bradycardic activities of Pasireotide.
Phenol
The risk or severity of methemoglobinemia can be increased when Ruxolitinib is combined with Phenol.
Pimavanserin
The metabolism of Ruxolitinib can be decreased when combined with Pimavanserin.
Pimozide
The metabolism of Ruxolitinib can be decreased when combined with Pimozide.
Pinaverium
Ruxolitinib may increase the bradycardic activities of Pinaverium.
Pindolol
Ruxolitinib may increase the bradycardic activities of Pindolol.
Pitolisant
The serum concentration of Ruxolitinib can be decreased when it is combined with Pitolisant.
Plazomicin
Ruxolitinib may decrease the excretion rate of Plazomicin which could result in a higher serum level.
Poractant alfa
Ruxolitinib may increase the bradycardic activities of Poractant alfa.
Posaconazole
The metabolism of Ruxolitinib can be decreased when combined with Posaconazole.
Potassium Iodide
The therapeutic efficacy of Potassium Iodide can be decreased when used in combination with Ruxolitinib.
Pramocaine
The risk or severity of methemoglobinemia can be increased when Ruxolitinib is combined with Pramocaine.
Prasterone
The metabolism of Ruxolitinib can be decreased when combined with Prasterone.
Pregabalin
Ruxolitinib may increase the bradycardic activities of Pregabalin.
Pretomanid
The metabolism of Ruxolitinib can be decreased when combined with Pretomanid.
Prilocaine
The risk or severity of methemoglobinemia can be increased when Ruxolitinib is combined with Prilocaine.
Procainamide
Ruxolitinib may decrease the excretion rate of Procainamide which could result in a higher serum level.
Procaine
The risk or severity of methemoglobinemia can be increased when Ruxolitinib is combined with Procaine.
Propafenone
Ruxolitinib may increase the bradycardic activities of Propafenone.
Proparacaine
The risk or severity of methemoglobinemia can be increased when Ruxolitinib is combined with Proparacaine.
Propranolol
Ruxolitinib may increase the bradycardic activities of Propranolol.
Propylthiouracil
The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Ruxolitinib.
Protirelin
The therapeutic efficacy of Protirelin can be decreased when used in combination with Ruxolitinib.
Rabies immune globulin, human
The therapeutic efficacy of Rabies immune globulin, human can be decreased when used in combination with Ruxolitinib.
Rabies virus inactivated antigen, A
The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Ruxolitinib.
Rabies virus inactivated antigen, B
The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Ruxolitinib.
Regorafenib
Ruxolitinib may increase the bradycardic activities of Regorafenib.
Remifentanil
Ruxolitinib may increase the bradycardic activities of Remifentanil.
Repotrectinib
The serum concentration of Ruxolitinib can be decreased when it is combined with Repotrectinib.
Respiratory syncytial virus vaccine, adjuvanted
The therapeutic efficacy of GSK-3844766A can be decreased when used in combination with Ruxolitinib.
Ribociclib
The metabolism of Ruxolitinib can be decreased when combined with Ribociclib.
Ritlecitinib
The serum concentration of Ruxolitinib can be increased when it is combined with Ritlecitinib.
Ritonavir
The metabolism of Ruxolitinib can be decreased when combined with Ritonavir.
Rivastigmine
Ruxolitinib may increase the bradycardic activities of Rivastigmine.
Ropivacaine
The risk or severity of methemoglobinemia can be increased when Ruxolitinib is combined with Ropivacaine.
Rosuvastatin
The metabolism of Ruxolitinib can be decreased when combined with Rosuvastatin.
Rotavirus vaccine
The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Ruxolitinib.
Rucaparib
The metabolism of Ruxolitinib can be decreased when combined with Rucaparib.
Salmon calcitonin
The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Ruxolitinib.
Saquinavir
The metabolism of Ruxolitinib can be decreased when combined with Saquinavir.
Satralizumab
The serum concentration of Ruxolitinib can be decreased when it is combined with Satralizumab.
Sipuleucel-T
The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Ruxolitinib.
Sotalol
Ruxolitinib may increase the bradycardic activities of Sotalol.
Sparsentan
The serum concentration of Ruxolitinib can be decreased when it is combined with Sparsentan.
Streptomycin
Ruxolitinib may decrease the excretion rate of Streptomycin which could result in a higher serum level.
Sufentanil
Ruxolitinib may increase the bradycardic activities of Sufentanil.
Sulfamethoxazole
The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Ruxolitinib.
Suvorexant
The metabolism of Ruxolitinib can be decreased when combined with Suvorexant.
Tacrolimus
Tacrolimus may increase the immunosuppressive activities of Ruxolitinib.
Tasimelteon
The metabolism of Ruxolitinib can be decreased when combined with Tasimelteon.
Tazemetostat
The metabolism of Ruxolitinib can be decreased when combined with Tazemetostat.
Telithromycin
The metabolism of Ruxolitinib can be decreased when combined with Telithromycin.
Telotristat ethyl
The serum concentration of Ruxolitinib can be decreased when it is combined with Telotristat ethyl.
Tenofovir alafenamide
The serum concentration of Tenofovir alafenamide can be increased when it is combined with Ruxolitinib.
Teriparatide
The therapeutic efficacy of Teriparatide can be decreased when used in combination with Ruxolitinib.
Tetracaine
The risk or severity of methemoglobinemia can be increased when Ruxolitinib is combined with Tetracaine.
Thyroid, porcine
The therapeutic efficacy of Thyroid, porcine can be decreased when used in combination with Ruxolitinib.
Thyrotropin alfa
The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Ruxolitinib.
Tick-borne encephalitis vaccine (whole virus, inactivated)
The therapeutic efficacy of Tick-borne encephalitis vaccine (whole virus, inactivated) can be decreased when used in combination with Ruxolitinib.
Timolol
Ruxolitinib may increase the bradycardic activities of Timolol.
Tipranavir
The metabolism of Ruxolitinib can be decreased when combined with Tipranavir.
Tizanidine
Ruxolitinib may increase the bradycardic activities of Tizanidine.
Tobramycin
Ruxolitinib may decrease the excretion rate of Tobramycin which could result in a higher serum level.
Tofacitinib
Ruxolitinib may increase the immunosuppressive activities of Tofacitinib.
Tovorafenib
The metabolism of Ruxolitinib can be increased when combined with Tovorafenib.
Trastuzumab
The risk or severity of neutropenia can be increased when Trastuzumab is combined with Ruxolitinib.
Tucatinib
The metabolism of Tucatinib can be decreased when combined with Ruxolitinib.
Typhoid vaccine
The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Ruxolitinib.
Typhoid Vi polysaccharide vaccine
The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Ruxolitinib.
Ublituximab
The risk or severity of infection can be increased when Ublituximab is combined with Ruxolitinib.
Vadadustat
The serum concentration of Ruxolitinib can be increased when it is combined with Vadadustat.
Vancomycin
Ruxolitinib may decrease the excretion rate of Vancomycin which could result in a higher serum level.
Varicella zoster vaccine (recombinant)
The therapeutic efficacy of Varicella zoster vaccine (recombinant) can be decreased when used in combination with Ruxolitinib.
Verapamil
Ruxolitinib may increase the bradycardic activities of Verapamil.
Vorapaxar
The metabolism of Ruxolitinib can be decreased when combined with Vorapaxar.
Voriconazole
The metabolism of Ruxolitinib can be decreased when combined with Voriconazole.
Xanomeline
The serum concentration of Ruxolitinib can be increased when it is combined with Xanomeline.
Zonisamide
Ruxolitinib may increase the bradycardic activities of Zonisamide.
Abacavir
Abacavir may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Abrocitinib
The metabolism of Abrocitinib can be decreased when combined with Ruxolitinib.
Aceclofenac
Aceclofenac may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Acenocoumarol
The risk or severity of bleeding can be increased when Acenocoumarol is combined with Ruxolitinib.
Acetylsalicylic acid
The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Ruxolitinib.
Aclidinium
Ruxolitinib may decrease the excretion rate of Aclidinium which could result in a higher serum level.
Acrivastine
Ruxolitinib may decrease the excretion rate of Acrivastine which could result in a higher serum level.
Acyclovir
Acyclovir may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Adefovir dipivoxil
Adefovir dipivoxil may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Albuterol
Salbutamol may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Albutrepenonacog alfa
Ruxolitinib may decrease the excretion rate of Albutrepenonacog alfa which could result in a higher serum level.
Allogeneic processed thymus tissue
The therapeutic efficacy of Allogeneic processed thymus tissue can be decreased when used in combination with Ruxolitinib.
Almasilate
Ruxolitinib may decrease the excretion rate of Almasilate which could result in a higher serum level.
Almotriptan
Almotriptan may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Alogliptin
Alogliptin may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Alosetron
The metabolism of Ruxolitinib can be decreased when combined with Alosetron.
Alprazolam
Alprazolam may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Alteplase
The risk or severity of bleeding can be increased when Alteplase is combined with Ruxolitinib.
Amantadine
Amantadine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Amiloride
Amiloride may increase the excretion rate of Ruxolitinib which could result in a lower serum level and potentially a reduction in efficacy.
Amitriptyline
Amitriptyline may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Ammonium chloride
Ammonium chloride may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Amoxicillin
Amoxicillin may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Amphetamine
Amphetamine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Amphotericin B
Amphotericin B may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Ampicillin
Ampicillin may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Anagrelide
The risk or severity of bleeding can be increased when Anagrelide is combined with Ruxolitinib.
Anthrax vaccine
The therapeutic efficacy of Anthrax vaccine can be decreased when used in combination with Ruxolitinib.
Antipyrine
Antipyrine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Antithrombin Alfa
The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Ruxolitinib.
Antithrombin III human
Ruxolitinib may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.
Apixaban
The risk or severity of bleeding can be increased when Apixaban is combined with Ruxolitinib.
Arformoterol
Arformoterol may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Argatroban
The risk or severity of bleeding can be increased when Argatroban is combined with Ruxolitinib.
Artemether
The metabolism of Ruxolitinib can be decreased when combined with Artemether.
Astaxanthin
The risk or severity of bleeding can be increased when Astaxanthin is combined with Ruxolitinib.
Atomoxetine
Atomoxetine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Auranofin
Auranofin may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Avatrombopag
The metabolism of Avatrombopag can be decreased when combined with Ruxolitinib.
Azelaic acid
Azelaic acid may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Azelastine
The metabolism of Ruxolitinib can be decreased when combined with Azelastine.
Aztreonam
Aztreonam may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Bacitracin
Bacitracin may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Baclofen
Baclofen may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Balsalazide
Balsalazide may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Benzatropine
Benzatropine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Benznidazole
Ruxolitinib may decrease the excretion rate of Benznidazole which could result in a higher serum level.
Bepotastine
Bepotastine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Betrixaban
The risk or severity of bleeding can be increased when Betrixaban is combined with Ruxolitinib.
Bicisate
Ruxolitinib may decrease the excretion rate of Bicisate which could result in a higher serum level.
Bismuth subgallate
Ruxolitinib may decrease the excretion rate of Bismuth subgallate which could result in a higher serum level.
Bivalirudin
The risk or severity of bleeding can be increased when Bivalirudin is combined with Ruxolitinib.
Brivaracetam
Brivaracetam may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Bromotheophylline
Bromotheophylline may increase the excretion rate of Ruxolitinib which could result in a lower serum level and potentially a reduction in efficacy.
Bumetanide
Bumetanide may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Bupropion
Bupropion may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Buspirone
Buspirone may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Cabozantinib
The metabolism of Ruxolitinib can be decreased when combined with Cabozantinib.
Canagliflozin
Ruxolitinib may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Candesartan cilexetil
The metabolism of Ruxolitinib can be decreased when combined with Candesartan cilexetil.
Cangrelor
The risk or severity of bleeding can be increased when Cangrelor is combined with Ruxolitinib.
Caplacizumab
The risk or severity of bleeding can be increased when Caplacizumab is combined with Ruxolitinib.
Carbamazepine
The metabolism of Ruxolitinib can be increased when combined with Carbamazepine.
Carbidopa
Carbidopa may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Cefaclor
Cefaclor may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Cefadroxil
Cefadroxil may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Cefazolin
Cefazolin may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Cefdinir
Cefdinir may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Cefditoren
Cefditoren may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Cefepime
Cefepime may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Cefotaxime
Cefotaxime may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Cefotetan
Cefotetan may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Cefoxitin
Cefoxitin may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Cefpodoxime
Cefpodoxime may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Cefprozil
Cefprozil may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Ceftaroline fosamil
Ceftaroline fosamil may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Ceftazidime
Ceftazidime may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Ceftibuten
Ceftibuten may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Ceftizoxime
Ceftizoxime may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Ceftolozane
Ruxolitinib may decrease the excretion rate of Ceftolozane which could result in a higher serum level.
Ceftriaxone
Ceftriaxone may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Cefuroxime
Cefuroxime may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Celecoxib
Celecoxib may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Cetirizine
Cetirizine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Cevimeline
Cevimeline may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Chloroquine
Chloroquine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Chlorothiazide
Chlorothiazide may increase the excretion rate of Ruxolitinib which could result in a lower serum level and potentially a reduction in efficacy.
Chlorthalidone
Chlorthalidone may increase the excretion rate of Ruxolitinib which could result in a lower serum level and potentially a reduction in efficacy.
Chlorzoxazone
Chlorzoxazone may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Choline salicylate
Ruxolitinib may decrease the excretion rate of Choline salicylate which could result in a higher serum level.
Chondroitin sulfate
Ruxolitinib may decrease the excretion rate of Chondroitin sulfate which could result in a higher serum level.
Chromic chloride
Ruxolitinib may decrease the excretion rate of Chromic chloride which could result in a higher serum level.
Chromium
Ruxolitinib may decrease the excretion rate of Chromium which could result in a higher serum level.
Chromium nicotinate
Ruxolitinib may decrease the excretion rate of Chromium nicotinate which could result in a higher serum level.
Cidofovir
Cidofovir may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Cilostazol
The risk or severity of bleeding can be increased when Cilostazol is combined with Ruxolitinib.
Cladribine
Ruxolitinib may increase the immunosuppressive activities of Cladribine.
Clomipramine
Clomipramine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Clonazepam
Clonazepam may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Clorazepic acid
Clorazepic acid may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Clove oil
Ruxolitinib may decrease the excretion rate of Clove oil which could result in a higher serum level.
Colchicine
Colchicine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Colistimethate
Colistimethate may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Conjugated estrogens
Conjugated estrogens may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Dabigatran etexilate
Dabigatran etexilate may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Dalfampridine
Dalfampridine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Dalteparin
The risk or severity of bleeding can be increased when Dalteparin is combined with Ruxolitinib.
Daptomycin
Daptomycin may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Deferiprone
Deferiprone may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Defibrotide
The risk or severity of bleeding can be increased when Defibrotide is combined with Ruxolitinib.
Desmopressin
Desmopressin may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Desogestrel
The metabolism of Ruxolitinib can be decreased when combined with Desogestrel.
Deuruxolitinib
The metabolism of Deuruxolitinib can be decreased when combined with Ruxolitinib.
Deutetrabenazine
Ruxolitinib may decrease the excretion rate of Deutetrabenazine which could result in a higher serum level.
Dexamethasone
The metabolism of Ruxolitinib can be increased when combined with Dexamethasone.
Dexpanthenol
Ruxolitinib may decrease the excretion rate of Dexpanthenol which could result in a higher serum level.
Dextran
Ruxolitinib may decrease the excretion rate of Dextran which could result in a higher serum level.
Dextromethorphan
The metabolism of Ruxolitinib can be decreased when combined with Dextromethorphan.
Diatrizoate
Diatrizoate may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Diazepam
Diazepam may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Diclofenac
Diclofenac may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Diclofenamide
Diclofenamide may increase the excretion rate of Ruxolitinib which could result in a lower serum level and potentially a reduction in efficacy.
Dicyclomine
Dicyclomine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Didanosine
Didanosine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Dienogest
Ruxolitinib may decrease the excretion rate of Dienogest which could result in a higher serum level.
Diflunisal
Diflunisal may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Dimercaprol
Dimercaprol may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Dipyridamole
The risk or severity of bleeding can be increased when Dipyridamole is combined with Ruxolitinib.
Disopyramide
Disopyramide may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
DL-Methylephedrine
Ruxolitinib may decrease the excretion rate of DL-Methylephedrine which could result in a higher serum level.
Dobutamine
Dobutamine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Dopamine
Dopamine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Doxepin
Doxepin may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Doxycycline
Doxycycline may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Droxidopa
Droxidopa may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Duloxetine
Duloxetine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Edetic acid
The risk or severity of bleeding can be increased when Edetic acid is combined with Ruxolitinib.
Edoxaban
Ruxolitinib may decrease the excretion rate of Edoxaban which could result in a higher serum level.
Edrophonium
Edrophonium may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Eletriptan
The metabolism of Ruxolitinib can be decreased when combined with Eletriptan.
Enalaprilat
Ruxolitinib may decrease the excretion rate of Enalaprilat which could result in a higher serum level.
Enoxaparin
The risk or severity of bleeding can be increased when Enoxaparin is combined with Ruxolitinib.
Eplerenone
Eplerenone may increase the excretion rate of Ruxolitinib which could result in a lower serum level and potentially a reduction in efficacy.
Epoprostenol
The risk or severity of bleeding can be increased when Epoprostenol is combined with Ruxolitinib.
Eptifibatide
The risk or severity of bleeding can be increased when Eptifibatide is combined with Ruxolitinib.
Ertapenem
Ertapenem may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Estazolam
Estazolam may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Estradiol
Estradiol may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Eszopiclone
Eszopiclone may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Etacrynic acid
Etacrynic acid may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Ethenzamide
Ethenzamide may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Ethinylestradiol
The metabolism of Ruxolitinib can be decreased when combined with Ethinylestradiol.
Etodolac
Etodolac may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Etomidate
Etomidate may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Etonogestrel
Etonogestrel may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Eucalyptus oil
Ruxolitinib may decrease the excretion rate of Eucalyptus oil which could result in a higher serum level.
Evening primrose oil
Ruxolitinib may decrease the excretion rate of Evening primrose oil which could result in a higher serum level.
Fenofibric acid
Ruxolitinib may decrease the excretion rate of Fenofibric acid which could result in a higher serum level.
Fenoldopam
Fenoldopam may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Fenoprofen
Fenoprofen may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Fesoterodine
Fesoterodine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Finerenone
Finerenone may increase the excretion rate of Ruxolitinib which could result in a lower serum level and potentially a reduction in efficacy.
Flavoxate
Flavoxate may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Florbetaben F-18
Ruxolitinib may decrease the excretion rate of Florbetaben (18F) which could result in a higher serum level.
Florbetapir F-18
Ruxolitinib may decrease the excretion rate of Florbetapir (18F) which could result in a higher serum level.
Fludeoxyglucose (18F)
Ruxolitinib may decrease the excretion rate of Fludeoxyglucose (18F) which could result in a higher serum level.
Flumazenil
Flumazenil may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Flurazepam
Flurazepam may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Flurbiprofen
Flurbiprofen may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Flutamide
Flutamide may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Folic acid
Folic acid may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Fomepizole
Fomepizole may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Fondaparinux
Fondaparinux may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Formoterol
The metabolism of Ruxolitinib can be decreased when combined with Formoterol.
Foscarnet
Foscarnet may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Fosfomycin
Fosfomycin may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Fosinopril
Fosinopril may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Fosphenytoin
The metabolism of Ruxolitinib can be increased when combined with Fosphenytoin.
Fruquintinib
The metabolism of Fruquintinib can be decreased when combined with Ruxolitinib.
Furosemide
Furosemide may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Gabapentin enacarbil
Gabapentin enacarbil may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Gadobenic acid
Gadobenic acid may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Gadodiamide
Gadodiamide may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Gadofosveset trisodium
Gadofosveset trisodium may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Gadoteric acid
Ruxolitinib may decrease the excretion rate of Gadoteric acid which could result in a higher serum level.
Gadoteridol
Gadoteridol may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Ganciclovir
Ganciclovir may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Givosiran
Givosiran may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Glimepiride
The metabolism of Ruxolitinib can be decreased when combined with Glimepiride.
Glipizide
Glipizide may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Golodirsen
Ruxolitinib may decrease the excretion rate of Golodirsen which could result in a higher serum level.
Goserelin
Goserelin may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Heparin
The risk or severity of bleeding can be increased when Heparin is combined with Ruxolitinib.
Hydrochlorothiazide
Hydrochlorothiazide may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Hydroflumethiazide
Hydroflumethiazide may increase the excretion rate of Ruxolitinib which could result in a lower serum level and potentially a reduction in efficacy.
Hydromorphone
Hydromorphone may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Hydroxocobalamin
Hydroxocobalamin may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Hydroxyethyl Starch
Ruxolitinib may decrease the excretion rate of Hydroxyethyl Starch which could result in a higher serum level.
Ibuprofen
Ibuprofen may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Ibutilide
Ibutilide may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Icatibant
Icatibant may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Icosapent
Icosapent may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Icosapent ethyl
The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Ruxolitinib.
Idarucizumab
Ruxolitinib may decrease the excretion rate of Idarucizumab which could result in a higher serum level.
Imipramine
Imipramine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Indapamide
Indapamide may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Indigotindisulfonic acid
Ruxolitinib may decrease the excretion rate of Indigotindisulfonic acid which could result in a higher serum level.
Inebilizumab
The risk or severity of infection can be increased when Ruxolitinib is combined with Inebilizumab.
Inositol
Ruxolitinib may decrease the excretion rate of Inositol which could result in a higher serum level.
Inotersen
Inotersen may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Iobenguane sulfate I-123
Ruxolitinib may decrease the excretion rate of Iobenguane sulfate I-123 which could result in a higher serum level.
Iodixanol
Iodixanol may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Ioflupane I-123
Ioflupane I-123 may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Iopromide
Ruxolitinib may decrease the excretion rate of Iopromide which could result in a higher serum level.
Iothalamic acid
Ruxolitinib may decrease the excretion rate of Iothalamic acid which could result in a higher serum level.
Ioversol
Ruxolitinib may decrease the excretion rate of Ioversol which could result in a higher serum level.
Ipecac
Ruxolitinib may decrease the excretion rate of Ipecac which could result in a higher serum level.
Ipilimumab
Ipilimumab may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Isosorbide
Isosorbide may increase the excretion rate of Ruxolitinib which could result in a lower serum level and potentially a reduction in efficacy.
Isosorbide mononitrate
Isosorbide mononitrate may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Isosulfan blue
Ruxolitinib may decrease the excretion rate of Isosulfan blue which could result in a higher serum level.
Isotretinoin
Isotretinoin may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Istradefylline
The metabolism of Istradefylline can be decreased when combined with Ruxolitinib.
Ixazomib
Ruxolitinib may decrease the excretion rate of Ixazomib which could result in a higher serum level.
Ketamine
Ketamine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Ketoprofen
Ketoprofen may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Ketorolac
Ketorolac may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Lamivudine
Lamivudine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Lansoprazole
The metabolism of Ruxolitinib can be decreased when combined with Lansoprazole.
Lazertinib
The metabolism of Ruxolitinib can be decreased when combined with Lazertinib.
Ledipasvir
Ruxolitinib may decrease the excretion rate of Ledipasvir which could result in a higher serum level.
Lenacapavir
The metabolism of Ruxolitinib can be decreased when combined with Lenacapavir.
Leuprolide
Leuprolide may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Levocarnitine
Levocarnitine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Levocetirizine
Levocetirizine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Levofloxacin
Levofloxacin may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Levomilnacipran
Ruxolitinib may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Levosalbutamol
Ruxolitinib may decrease the excretion rate of Levosalbutamol which could result in a higher serum level.
Lisinopril
Lisinopril may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Lithium citrate
Lithium citrate may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Lixisenatide
Ruxolitinib may decrease the excretion rate of Lixisenatide which could result in a higher serum level.
Lofexidine
Lofexidine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Lorazepam
Lorazepam may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Losartan
The metabolism of Ruxolitinib can be decreased when combined with Losartan.
Lubiprostone
Lubiprostone may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Macitentan
Ruxolitinib may decrease the excretion rate of Macitentan which could result in a higher serum level.
Magnesium carbonate
Ruxolitinib may decrease the excretion rate of Magnesium carbonate which could result in a higher serum level.
Magnesium chloride
Ruxolitinib may decrease the excretion rate of Magnesium chloride which could result in a higher serum level.
Magnesium hydroxide
Ruxolitinib may decrease the excretion rate of Magnesium hydroxide which could result in a higher serum level.
Magnesium salicylate
Magnesium salicylate may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Magnesium trisilicate
Ruxolitinib may decrease the excretion rate of Magnesium trisilicate which could result in a higher serum level.
Mannitol
Mannitol may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Maprotiline
Maprotiline may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Mavorixafor
The metabolism of Ruxolitinib can be decreased when combined with Mavorixafor.
Mecamylamine
Mecamylamine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Meclofenamic acid
Meclofenamic acid may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Mefenamic acid
Mefenamic acid may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Megestrol acetate
Megestrol acetate may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Memantine
Memantine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Meropenem
Meropenem may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Mesalazine
Mesalazine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Metamfetamine
Metamfetamine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Metaxalone
Metaxalone may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Metformin
Metformin may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Methazolamide
Methazolamide may increase the excretion rate of Ruxolitinib which could result in a lower serum level and potentially a reduction in efficacy.
Methoxsalen
Methoxsalen may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Methylnaltrexone
Methylnaltrexone may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Methyltestosterone
Methyltestosterone may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Metoclopramide
Metoclopramide may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Metolazone
Metolazone may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Metreleptin
The metabolism of Ruxolitinib can be increased when combined with Metreleptin.
Migalastat
Migalastat may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Milrinone
Milrinone may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Mirabegron
Ruxolitinib may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Mitapivat
The metabolism of Ruxolitinib can be increased when combined with Mitapivat.
Mitotane
The metabolism of Ruxolitinib can be increased when combined with Mitotane.
Montelukast
The metabolism of Ruxolitinib can be decreased when combined with Montelukast.
Mosunetuzumab
The metabolism of Ruxolitinib can be decreased when combined with Mosunetuzumab.
N-acetyltyrosine
Ruxolitinib may decrease the excretion rate of N-acetyltyrosine which could result in a higher serum level.
Nabilone
The metabolism of Ruxolitinib can be decreased when combined with Nabilone.
Nabumetone
Nabumetone may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Naldemedine
Ruxolitinib may decrease the excretion rate of Naldemedine which could result in a higher serum level.
Nalmefene
Nalmefene may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Naloxone
Naloxone may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Naproxen
Naproxen may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Nateglinide
Nateglinide may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Nedocromil
Nedocromil may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Nevirapine
The metabolism of Ruxolitinib can be decreased when combined with Nevirapine.
Nitric Oxide
Nitric Oxide may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Nitrofurantoin
Nitrofurantoin may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Nitroprusside
Nitroprusside may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Octinoxate
Ruxolitinib may decrease the excretion rate of Octinoxate which could result in a higher serum level.
Olodaterol
The metabolism of Olodaterol can be decreased when combined with Ruxolitinib.
Olsalazine
Olsalazine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Omaveloxolone
The serum concentration of Ruxolitinib can be decreased when it is combined with Omaveloxolone.
Ondansetron
The metabolism of Ruxolitinib can be decreased when combined with Ondansetron.
Opium
Ruxolitinib may decrease the excretion rate of Opium which could result in a higher serum level.
Oseltamivir
Oseltamivir may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Ospemifene
The metabolism of Ruxolitinib can be decreased when combined with Ospemifene.
Oxacillin
Oxacillin may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Oxaprozin
Oxaprozin may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Oxazepam
Oxazepam may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Oxybenzone
Oxybenzone may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Oxyquinoline
Ruxolitinib may decrease the excretion rate of Oxyquinoline which could result in a higher serum level.
Paliperidone
Paliperidone may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Palonosetron
Palonosetron may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Pamidronic acid
Pamidronic acid may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Pantoprazole
Pantoprazole may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Parecoxib
Parecoxib may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Paromomycin
Paromomycin may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Pentamidine
Pentamidine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Pentetic acid
Ruxolitinib may decrease the excretion rate of Pentetic acid which could result in a higher serum level.
Pentobarbital
The metabolism of Ruxolitinib can be increased when combined with Pentobarbital.
Pentosan polysulfate
The risk or severity of bleeding can be increased when Pentosan polysulfate is combined with Ruxolitinib.
Pentoxifylline
The risk or severity of bleeding can be increased when Pentoxifylline is combined with Ruxolitinib.
Perindopril
Perindopril may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Permethrin
Permethrin may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Phenazopyridine
Phenazopyridine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Phenelzine
Phenelzine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Phenobarbital
The metabolism of Ruxolitinib can be increased when combined with Phenobarbital.
Phenytoin
The metabolism of Ruxolitinib can be increased when combined with Phenytoin.
Phosphoric acid
Ruxolitinib may decrease the excretion rate of Phosphoric acid which could result in a higher serum level.
Phylloquinone
Phylloquinone may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Picosulfuric acid
Ruxolitinib may decrease the excretion rate of Picosulfuric acid which could result in a higher serum level.
Piperacillin
Piperacillin may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Piroxicam
Piroxicam may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Plerixafor
Plerixafor may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Polythiazide
Polythiazide may increase the excretion rate of Ruxolitinib which could result in a lower serum level and potentially a reduction in efficacy.
Potassium
Potassium may increase the excretion rate of Ruxolitinib which could result in a lower serum level and potentially a reduction in efficacy.
Potassium acetate
Ruxolitinib may decrease the excretion rate of Potassium acetate which could result in a higher serum level.
Potassium bicarbonate
Ruxolitinib may decrease the excretion rate of Potassium bicarbonate which could result in a higher serum level.
Potassium cation
Potassium cation may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Potassium chloride
Potassium chloride may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Potassium citrate
Potassium citrate may increase the excretion rate of Ruxolitinib which could result in a lower serum level and potentially a reduction in efficacy.
Potassium nitrate
Ruxolitinib may decrease the excretion rate of Potassium nitrate which could result in a higher serum level.
Potassium sulfate
Ruxolitinib may decrease the excretion rate of Potassium sulfate which could result in a higher serum level.
Pralidoxime
Pralidoxime may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Pramipexole
Pramipexole may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Prasugrel
The risk or severity of bleeding can be increased when Prasugrel is combined with Ruxolitinib.
Primidone
The metabolism of Ruxolitinib can be increased when combined with Primidone.
Procaine benzylpenicillin
Ruxolitinib may decrease the excretion rate of Procaine benzylpenicillin which could result in a higher serum level.
Proguanil
The metabolism of Ruxolitinib can be decreased when combined with Proguanil.
Propantheline
Propantheline may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Propyphenazone
Propyphenazone may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Protein C
The risk or severity of bleeding can be increased when Protein C is combined with Ruxolitinib.
Protein S human
The risk or severity of bleeding can be increased when Protein S human is combined with Ruxolitinib.
Prucalopride
Prucalopride may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Pyrantel
Ruxolitinib may decrease the excretion rate of Pyrantel which could result in a higher serum level.
Pyrazinamide
Pyrazinamide may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Pyridoxine
Pyridoxine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Quetiapine
Quetiapine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Rabeprazole
Rabeprazole may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Ramelteon
Ramelteon may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Ranitidine
Ranitidine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Rasagiline
Rasagiline may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Reserpine
Reserpine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Resorcinol
Ruxolitinib may decrease the excretion rate of Resorcinol which could result in a higher serum level.
Resveratrol
The risk or severity of bleeding can be increased when Resveratrol is combined with Ruxolitinib.
Ribavirin
Ribavirin may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Rifampin
The metabolism of Ruxolitinib can be increased when combined with Rifampicin.
Rifapentine
The metabolism of Ruxolitinib can be increased when combined with Rifapentine.
Rivaroxaban
Rivaroxaban may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Rizatriptan
Rizatriptan may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Roflumilast
Roflumilast may increase the immunosuppressive activities of Ruxolitinib.
Rosiglitazone
Rosiglitazone may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Sacubitril
Ruxolitinib may decrease the excretion rate of Sacubitril which could result in a higher serum level.
Salicylamide
Salicylamide may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Salicylic acid
Salicylic acid may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Salsalate
Salsalate may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Saxagliptin
Saxagliptin may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Seladelpar
The metabolism of Seladelpar can be decreased when combined with Ruxolitinib.
Selegiline
The metabolism of Ruxolitinib can be decreased when combined with Selegiline.
Selenious acid
Ruxolitinib may decrease the excretion rate of Selenious acid which could result in a higher serum level.
Selenium
Ruxolitinib may decrease the excretion rate of Selenium which could result in a higher serum level.
Selumetinib
The metabolism of Selumetinib can be decreased when combined with Ruxolitinib.
Sitagliptin
Sitagliptin may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Sodium acetate
Ruxolitinib may decrease the excretion rate of Sodium acetate which could result in a higher serum level.
Sodium citrate
The risk or severity of bleeding can be increased when Sodium citrate is combined with Ruxolitinib.
Sodium fluoride
Ruxolitinib may decrease the excretion rate of Sodium fluoride which could result in a higher serum level.
Sodium sulfate
Ruxolitinib may decrease the excretion rate of Sodium sulfate which could result in a higher serum level.
Sofosbuvir
Ruxolitinib may decrease the excretion rate of Sofosbuvir which could result in a higher serum level.
Solriamfetol
Ruxolitinib may decrease the excretion rate of Solriamfetol which could result in a higher serum level.
Somatrogon
The metabolism of Ruxolitinib can be increased when combined with Somatrogon.
Sorbitol
Sorbitol may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Spironolactone
Spironolactone may increase the excretion rate of Ruxolitinib which could result in a lower serum level and potentially a reduction in efficacy.
Sucralfate
Sucralfate may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Sulbactam
Ruxolitinib may decrease the excretion rate of Sulbactam which could result in a higher serum level.
Sulindac
Sulindac may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Sumatriptan
Sumatriptan may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Suzetrigine
The metabolism of Ruxolitinib can be increased when combined with Suzetrigine.
Synthetic Conjugated Estrogens, A
Ruxolitinib may decrease the excretion rate of Synthetic Conjugated Estrogens, A which could result in a higher serum level.
Synthetic Conjugated Estrogens, B
Ruxolitinib may decrease the excretion rate of Synthetic Conjugated Estrogens, B which could result in a higher serum level.
Tadalafil
Tadalafil may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Tamsulosin
Tamsulosin may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Technetium Tc-99m exametazime
Ruxolitinib may decrease the excretion rate of Technetium Tc-99m exametazime which could result in a higher serum level.
Technetium Tc-99m pyrophosphate
Ruxolitinib may decrease the excretion rate of Technetium Tc-99m pyrophosphate which could result in a higher serum level.
Tedizolid phosphate
The risk or severity of myelosuppression can be increased when Ruxolitinib is combined with Tedizolid phosphate.
Teduglutide
Ruxolitinib may decrease the excretion rate of Teduglutide which could result in a higher serum level.
Telavancin
Telavancin may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Temazepam
Temazepam may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Tenecteplase
The risk or severity of bleeding can be increased when Tenecteplase is combined with Ruxolitinib.
Tenofovir disoproxil
Tenofovir disoproxil may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Terbutaline
Terbutaline may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Testosterone cypionate
Ruxolitinib may decrease the excretion rate of Testosterone cypionate which could result in a higher serum level.
Testosterone enanthate
Ruxolitinib may decrease the excretion rate of Testosterone enanthate which could result in a higher serum level.
Testosterone propionate
Testosterone propionate may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Testosterone undecanoate
Ruxolitinib may decrease the excretion rate of Testosterone undecanoate which could result in a higher serum level.
Tetradecyl hydrogen sulfate (ester)
Ruxolitinib may decrease the excretion rate of Tetradecyl hydrogen sulfate (ester) which could result in a higher serum level.
Tinidazole
Tinidazole may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Tinzaparin
The risk or severity of bleeding can be increased when Tinzaparin is combined with Ruxolitinib.
Tiopronin
Tiopronin may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Tiotropium
Tiotropium may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Tirofiban
The risk or severity of bleeding can be increased when Tirofiban is combined with Ruxolitinib.
Tocopherol
Ruxolitinib may decrease the excretion rate of Tocopherol which could result in a higher serum level.
Tocopherylquinone
The risk or severity of bleeding can be increased when Tocopherylquinone is combined with Ruxolitinib.
Tolazamide
Tolazamide may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Tolcapone
Tolcapone may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Tolmetin
Tolmetin may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Tolterodine
Tolterodine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Tolvaptan
Tolvaptan may increase the excretion rate of Ruxolitinib which could result in a lower serum level and potentially a reduction in efficacy.
Tramadol
Tramadol may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Trametinib
Ruxolitinib may decrease the excretion rate of Trametinib which could result in a higher serum level.
Treprostinil
The metabolism of Ruxolitinib can be decreased when combined with Treprostinil.
Triamterene
Triamterene may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Triazolam
Triazolam may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Triethylenetetramine
Triethylenetetramine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Trimethoprim
Trimethoprim may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Trimetrexate
Trimetrexate may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Trimipramine
The metabolism of Ruxolitinib can be decreased when combined with Trimipramine.
Trofinetide
The metabolism of Ruxolitinib can be decreased when combined with Trofinetide.
Troxerutin
The risk or severity of bleeding can be increased when Troxerutin is combined with Ruxolitinib.
Urokinase
The risk or severity of bleeding can be increased when Urokinase is combined with Ruxolitinib.
Vaborbactam
Ruxolitinib may decrease the excretion rate of Vaborbactam which could result in a higher serum level.
Valaciclovir
Valaciclovir may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Valbenazine
Ruxolitinib may decrease the excretion rate of Valbenazine which could result in a higher serum level.
Valganciclovir
Valganciclovir may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Vardenafil
The metabolism of Ruxolitinib can be decreased when combined with Vardenafil.
Varenicline
Varenicline may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Venlafaxine
Venlafaxine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Vibrio cholerae CVD 103-HgR strain live antigen
The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Ruxolitinib.
Viloxazine
The metabolism of Ruxolitinib can be decreased when combined with Viloxazine.
Vortioxetine
Ruxolitinib may decrease the excretion rate of Vortioxetine which could result in a higher serum level.
Zaleplon
Zaleplon may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Zanamivir
Zanamivir may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Zileuton
The metabolism of Ruxolitinib can be decreased when combined with Zileuton.
Zolpidem
The metabolism of Ruxolitinib can be decreased when combined with Zolpidem.